Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors
Sarah C. Markt(Harvard University), Christopher J. Sweeney(Dana-Farber Cancer Institute), Alexi A. Wright(Harvard University), Brandon A. Mahal(Harvard University), Brandon Bernard(Dana-Farber Brigham Cancer Center), Rowan Miller(University College Hospital), Laurence Albigès(Institut Gustave Roussy), Lindsay A. Frazier(Dana (United States)), Clair J. Beard(Oslo University Hospital), Carlos Lago‐Hernandez(Dana-Farber Brigham Cancer Center)
Cited by 63
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Health Care Costs in the Last Week of Life
|Archives of Internal Medicine|2009|900